Thank you very much, Madam Chair.
Once again, I thank all five witnesses for being here this morning.
For my second turn—and likely my last—I will address you, Ms. Daniel.
You talked about biomarkers. We obviously heard about it before, but I am struck by it every time. Correct me if I’m wrong, but you said 40% to 70% of them were present in Western Africa.
Are these, in fact, breast cancer biomarkers? I am not sure, because opening statements sometimes go by quickly. You also said the percentage was 20% to 22% in the United States and 10% in Canada.
Are those the right numbers? Did I understand correctly?